Overview of Antiverse’s Progress
Antiverse, a techbio company focused on antibody design, has successfully closed a €4.2 million seed funding round. This investment boosts its total equity financing to €8.6 million. The company aims to transform the landscape of antibody development by utilizing generative AI technology.
Key Highlights of the Funding Round
- The funding round was led by i&i Biotech Fund I and Kadmos Capital, with support from existing investors.
- The investment will accelerate the development of Antiverse’s AI-driven antibody platform and expand its teams.
- Antiverse targets challenging drug targets like G-protein-coupled receptors (GPCRs) and ion channels, which have been difficult to address in the past.
- The company can now reduce antibody discovery time to just six months using machine learning and target-specific libraries.
Importance of the Investment
The new funding is crucial for Antiverse as it enhances collaborations with pharmaceutical and biotech companies. The expansion into new facilities in Boston and Prague will support a growing pipeline of projects. With one-third of FDA-approved drugs targeting GPCRs, the potential impact of Antiverse’s work is significant. The investment will help bring innovative therapies to patients worldwide, addressing a critical gap in drug development for complex diseases.
